Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pola-R-GemOx for Relapsed/Refractory DLBCL
NCT07001540Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- May 2025
- Primary completion
- Nov 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of polatuzumab vedotin in diffuse large B-cell lymphoma (DLBCL), sponsored by Fudan University. Started May 2025; status: recruiting.
02
Drugs
polatuzumab vedotin
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT07001540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07001540.